Genesis Therapeutics is a team of drug hunters, deep learning researchers, and software engineers collaborating to drive AI in biochemistry, discovering and developing new therapies for patients suffering from severe disorders.

Genesis Therapeutics

Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery.

The GEMS platform integrates deep learning-based predictive models, molecular simulations, and molecular generative AI. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization. 

We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022) and Genentech (signed in 2020).

Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. We are rapidly growing our team with a variety of openings on our machine learning, computational chemistry, and software teams (primarily located in the Bay Area) and our chemistry, biology, and clinical teams (primarily located in San Diego). To learn more about Genesis Therapeutics, or current employment opportunities, please visit our website.

T. Rowe Price

Ulu Ventures

Felicis

Rock Springs Capital

Open Field Capital

Propagator Ventures

Radical Ventures

Jazz Venture Partners

Menlo Ventures

Jeffrey Rothschild

BlackRock

Fidelity

Andreessen Horowitz

Fidelity Management and Research Company

Next week, Genesis’ CEO, Dr. Evan Feinberg, PhD, will speak at the 2024 WuXi AppTec Global Forum alongside fellow industry leaders to discuss how platform solutions, such as Genesis’ AI-enabled drug discovery platform, are driving the development of medicines that improve the lives of patients living with difficult-to-treat disease.

Learn more about the panel, “Delivering on Platform Solutions,” and the forum here: https://lnkd.in/ggbqGe2F

A few members of our technical team will be at MoML tomorrow. We’re looking forward to learning about the latest in molecular ML and connecting with old and new fiends. Come say hi 👋, find out what our team has been up to 🤓, and learn about opportunities at Genesis! 🚀

Genesis’ CEO and co-founder Evan Feinberg sat down with a16z Bio + Health and Health’s Vijay Pande, PhD on this week’s episode of Bio Eats World to discuss AI in small-molecule drug design and the founding of Genesis, from Evan’s early days at Stanford to the company’s recent $200M series B.

Listen to the podcast episode here: https://lnkd.in/g6-Zv-kQ

Genesis is excited to announce $200 million in Series B funding, which we’ll use to supercharge our AI platform and accelerate our pipeline with an eye toward the clinic.

Read more in today’s press release: https://lnkd.in/g3utJ3W9

AI:GENESISTHERAPEUTICS

Genesis Therapeutics

locale

market

industry

website

crunchbase

linkedin

founding date

investor of

Metrics